In brief, we found for the first time that shRNA-mediated repression of DNAJC19 greatly attenuated tumor cell growth and metastasis by regulating PI3K/AKT signaling, providing a novel therapeutic target for NSCLC patients. This evidence concerns the gene PIK3CA and neoplasm.